Data Sheet 1_Electroacupuncture treatment can improve cognitive impairment in spontaneously hypertensive rats: a preliminary DTI study.docx by Ji-peng Liu (14764009)

“…</p>Results<p>The results showed that electroacupuncture significantly decreased systolic and diastolic blood pressure and enhanced spatial learning and memory in SHRs. …”

Table 1_Eculizumab for the acute attack of neuromyelitis optica spectrum disorder.docx by Qingqing Zhuang (22109089)

“…Visual field mean deviation improved from −22.4 dB to −2.0 dB (p = 0.008). …”

Analysis diagram of economic carrying system. by Hui Li (32376)

“…Our results indicate significant changes in land types within the TGRR from 1986 to 2020, with decreases in arable land, forest land, and grassland, while water bodies, building land, and unused land increased. …”

Analysis diagram of population carrying system. by Hui Li (32376)

“…Our results indicate significant changes in land types within the TGRR from 1986 to 2020, with decreases in arable land, forest land, and grassland, while water bodies, building land, and unused land increased. …”

Image 4_Changes in symptom pattern in Meniere's disease by duration: the need for comprehensive management.tif by Ilmari Pyykkö (2855153)

“…The study population comprised 79.5% females and 20.5% males, with a mean age of 63 years and an average disease duration of 15.2 years.…”

Image 5_Changes in symptom pattern in Meniere's disease by duration: the need for comprehensive management.tif by Ilmari Pyykkö (2855153)

“…The study population comprised 79.5% females and 20.5% males, with a mean age of 63 years and an average disease duration of 15.2 years.…”

Image 1_Changes in symptom pattern in Meniere's disease by duration: the need for comprehensive management.tif by Ilmari Pyykkö (2855153)

“…The study population comprised 79.5% females and 20.5% males, with a mean age of 63 years and an average disease duration of 15.2 years.…”

Image 2_Changes in symptom pattern in Meniere's disease by duration: the need for comprehensive management.tif by Ilmari Pyykkö (2855153)

“…The study population comprised 79.5% females and 20.5% males, with a mean age of 63 years and an average disease duration of 15.2 years.…”

EU Data.csv<b>EU Data-1:</b> Age, sex, and medications used in patients with Parkinson’s disease.<b>EU Data-2:</b> Experimental parameters during off and on states of anti-Parkinso... by Eiichirou Urasaki (20502995)

“…The rate of CSP duration shortening during cold pressure was significantly greater under the drug-on condition than under the drug-off condition (mean, 22% vs. 12%; p < 0.01). …”

Table 1_Clinical characteristics and treatment of hepatic portal venous gas: case series and literature review.docx by Hao-Ran Wei (18833288)

“…Patients presented with decreased red blood cell and hemoglobin counts, and increased white blood cell, neutrophil, C-reactive protein, and D-dimer levels. …”

Data Sheet 1_Changes in symptom pattern in Meniere's disease by duration: the need for comprehensive management.pdf by Ilmari Pyykkö (2855153)

“…The study population comprised 79.5% females and 20.5% males, with a mean age of 63 years and an average disease duration of 15.2 years.…”

Table 1_Obinutuzumab in systemic lupus erythematosus: a real-world experience.docx by Chunmei Wu (3202050)

“…By week 48, 37.5% achieved DORIS remission, 32.1% LLDAS, and 19.6% remained clinically stable. Mean SLEDAI-2K decreased from 11.75 ± 9.31 (range: 0 to 46) to 1.45± 1.93 (range: 0 to 8). …”

Image 3_Changes in symptom pattern in Meniere's disease by duration: the need for comprehensive management.tif by Ilmari Pyykkö (2855153)

“…The study population comprised 79.5% females and 20.5% males, with a mean age of 63 years and an average disease duration of 15.2 years.…”

Image 2_Astragaloside IV alleviates GDM via regulating gut microbiota and gut microbiota metabolomic.tif by Fengge Wang (4347442)

“…</p>Results<p>After the 25-day intervention, the GDM model + AS IV group showed significantly decreased fasting blood glucose levels (p = 0.0003), mean insulin levels (p = 0.0001), and insulin resistance index (p = 0.0001). …”

Image 1_Astragaloside IV alleviates GDM via regulating gut microbiota and gut microbiota metabolomic.tif by Fengge Wang (4347442)

“…</p>Results<p>After the 25-day intervention, the GDM model + AS IV group showed significantly decreased fasting blood glucose levels (p = 0.0003), mean insulin levels (p = 0.0001), and insulin resistance index (p = 0.0001). …”

Data Sheet 1_Longitudinal changes in bodyweight, body condition, and muscle condition in ageing pet cats: findings from the Cat Prospective Ageing and Welfare Study.docx by Christine R. Pye (22118977)

“…All three metrics showed significant non-linear associations with age. Bodyweight increased slightly from age 7 to 10 (estimated marginal mean 4.77–4.82 kg) before decreasing to 4.30 kg by age 16 years. …”

Table 1_Astragaloside IV alleviates GDM via regulating gut microbiota and gut microbiota metabolomic.xlsx by Fengge Wang (4347442)

“…</p>Results<p>After the 25-day intervention, the GDM model + AS IV group showed significantly decreased fasting blood glucose levels (p = 0.0003), mean insulin levels (p = 0.0001), and insulin resistance index (p = 0.0001). …”

Table 2_Astragaloside IV alleviates GDM via regulating gut microbiota and gut microbiota metabolomic.xlsx by Fengge Wang (4347442)

“…</p>Results<p>After the 25-day intervention, the GDM model + AS IV group showed significantly decreased fasting blood glucose levels (p = 0.0003), mean insulin levels (p = 0.0001), and insulin resistance index (p = 0.0001). …”

Supplementary Material for: The impact of left ventricular structure and function on mortality in patients with aortic valve infective endocarditis treated with aortic valve replac... by figshare admin karger (2628495)

“…The mean LVEF was 54±11% preoperatively, decreasing to 51±11% postoperatively. …”

DataSheet1_Erlotinib regulates short-term memory, tau/Aβ pathology, and astrogliosis in mouse models of AD.doc by Hyun-ju Lee (7550741)

“…Introduction<p>Erlotinib is an epidermal growth factor receptor (EGFR) inhibitor that is approved by the FDA to treat non-small cell lung cancer (NSCLC). Several membrane receptors, including EGFR, interact with amyloid β (Aβ), raising the possibility that erlotinib could have therapeutic effects on Alzheimer's disease (AD). …”